Loading
A phase 1/2 trial of ST-1898 tablets in renal cell carcinoma, run by Beijing Scitech-Mq Pharmaceuticals Limited, active and no longer recruiting.
Study of ST-1898 in Advanced Renal Cell Carcinoma is a phase 1/2 interventional study registered as NCT06127238 by Beijing Scitech-Mq Pharmaceuticals Limited, with 90 participants enrolled, started 2023-02-07 and due to reach its primary completion in 2025-12. Interventions recorded: ST-1898 tablets.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Beijing Scitech-Mq Pharmaceuticals and the tag pipeline.
Shares Beijing Scitech-Mq Pharmaceuticals and the tag pipeline.
Shares Renal cell carcinoma and the tag pipeline.
Shares Renal cell carcinoma and the tag pipeline.
Shares Renal cell carcinoma and the tag pipeline.
Shares Renal cell carcinoma and the tag pipeline.
Shares Renal cell carcinoma and the tag pipeline.
Shares Renal cell carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/